Prelude Therapeutics IncPRLD
Price (close)
$3.99
Market cap
$318.4M
P/E
—
Revenue (TTM)
$22.4M
Net income
-$60.5M
Dividend yield
—
1-year total return
227.0%
Net margin
-269.7%
Revenue growth
220.3%
Debt / equity
—
What Prelude Therapeutics Inc does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $7.0M | $12.1M |
| Net income | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| Free cash flow | -$46.8M | -$85.9M | -$86.7M | -$110.6M | -$103.7M | -$56.4M |
More on PRLD.
- Prelude Therapeutics Inc summary
- Prelude Therapeutics Inc financial statements
- Prelude Therapeutics Inc key metrics
- Prelude Therapeutics Inc health scores and style box
- Prelude Therapeutics Inc earnings
- Prelude Therapeutics Inc dividends
- Prelude Therapeutics Inc valuation
- Prelude Therapeutics Inc ownership and insiders
- Prelude Therapeutics Inc peers
Figures from Prelude Therapeutics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.